Valuation: Novartis AG

Market Cap 265B 230B 217B 197B 370B 25,440B 372B 2,593B 1,002B 12,904B 996B 974B 41,130B P/E 2026 *
19.7x
P/E 2027 * 16.6x
Enterprise Value 297B 257B 243B 221B 414B 28,470B 416B 2,902B 1,121B 14,440B 1,115B 1,090B 46,027B EV / Sales 2026 *
5.15x
EV / Sales 2027 * 4.78x
Free-Float
91.66%
Yield 2026 *
3.12%
Yield 2027 * 3.26%
Manager TitleAgeSince
Chief Executive Officer 50 31/01/2018
Director of Finance/CFO - 15/03/2026
Compliance Officer 58 13/04/2025
Director TitleAgeSince
Director/Board Member 67 31/12/2014
Director/Board Member 69 31/12/2015
Director/Board Member 61 31/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-0.77% - - 265B
+0.15%+1.21%+48.79%+97.65% 1,014B
+0.03%+0.07%+51.47%+65.55% 644B
-0.20%+4.62%+21.39%+72.57% 464B
-0.58%+4.26%+40.29%+38.70% 354B
+0.74%+2.35%+17.96%+23.87% 265B
+1.09%+4.17%+6.96%+10.93% 253B
+0.19%-3.81%+37.81%+44.35% 203B
+0.97%-5.64%-24.09%-59.10% 186B
+0.94%+1.39%+33.21%+95.16% 183B
Average +0.34%+0.96%+25.98%+43.30% 396.31B
Weighted average by Cap. +0.20%+1.41%+34.38%+59.76%

Financials

2026 *2027 *
Net sales 57.65B 49.96B 47.22B 42.87B 80.35B 5,531B 80.83B 564B 218B 2,805B 217B 212B 8,941B 61.34B 53.15B 50.24B 45.61B 85.48B 5,884B 85.99B 600B 232B 2,984B 230B 225B 9,513B
Net income 14.2B 12.3B 11.63B 10.56B 19.78B 1,362B 19.9B 139B 53.64B 691B 53.33B 52.14B 2,202B 15.76B 13.65B 12.9B 11.72B 21.96B 1,511B 22.09B 154B 59.53B 767B 59.18B 57.87B 2,444B
Net Debt 31.58B 27.37B 25.87B 23.48B 44.01B 3,029B 44.27B 309B 119B 1,537B 119B 116B 4,898B 27.88B 24.16B 22.84B 20.73B 38.86B 2,675B 39.09B 273B 105B 1,357B 105B 102B 4,324B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
139.52USD
Average target price
152.93USD
Spread / Average Target
+9.61%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!